March 23, 2021 — The Sumaira Foundation for NMO (TSF) and Portal Instruments are pleased to announce their partnership as of March 2021.
Portal Instruments and TSF share a joint vision of creating a better experience and improved treatment options for patients diagnosed with neuromyeltitis optica spectrum disorder.
Established in 2014, The Sumaira Foundation for NMO (TSF) is a 501(c)(3) organization founded and led by an NMO patient that is dedicated to generating global awareness of neuromyelitis optica spectrum disorder (NMOSD), fundraising to help find a cure, and creating a community of support for patients + their caregivers.
Portal Instruments is developing and commercializing a highly innovative needle-free jet injection platform that transforms the drug delivery experience for patients suffering from chronic disease. Portal’s aim is to replace all needles and syringes with a safe, fast, and connected device and empower the patient to holistically manage their chronic condition.
Barbara Taylor, VP of Commercial and Marketing at Portal Instruments said “Portal Instruments is thrilled to be working with The Sumaira Foundation as we share a vision of supporting and empowering patients. Portal sees the need to offer a needle-free solution to NMO patients and we are excited to be working with TSF and the NMO community to make this happen.”
Elated about the partnership, Sumaira Ahmed, TSF Founder and Executive Director, adds, “As a patient who is not particularly eager to be ‘hooked up to an infusion pole’ as frequently as our treatment plans often require, I am eager to introduce the Portal device to our patient population. I genuinely believe that Portal’s innovative drug delivery method will afford our community with a semblance of independence – something many of us feel we lost after getting diagnosed with NMOSD.”